[Acute thrombocytopenia after obinutuzumab administration in a patient with relapsed follicular lymphoma].
[Acute thrombocytopenia after obinutuzumab administration in a patient with relapsed follicular lymphoma].
复制标题
[复发性滤泡性淋巴瘤患者服用奥比妥珠单抗后出现急性血小板减少症]。
DOI：
10.11406/rinketsu.61.1616
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Toru Takahashi
中科院分区：
文献类型：
--
作者：
Kohei Sakai;T. Matsumura;R. Hamada;T. Tominaga;Toru Takahashi
一位64岁女性因滤泡性淋巴瘤复发而入院。她的淋巴瘤给予Obinutuzumab （OBZ）和苯达莫司汀（GB）治疗，第一个疗程后观察到血小板减少需要血小板输注。虽然苯达莫司汀的剂量已经减少，但在第二次疗程后再次观察到她的血小板减少。经过4个疗程的GB治疗后，患者的淋巴瘤完全缓解，并转入OBZ维持治疗。然而，在单独使用OBZ维持治疗期间，再次观察到血小板减少。详细观察OBZ给药后血小板计数随时间的变化，OBZ给药结束后1小时血小板计数开始下降，6小时后下降一半，给药后4天达到最低，10天后逐渐恢复。虽然OBZ给药相关的血小板减少是一种相对常见的并发症，但在给药后24小时内急性血小板减少是罕见的。然而，在本病例中，血小板减少症可能在给药后极短的时间内进展，临床医生有必要注意OBZ治疗。
A 64-year-old woman was admitted to our hospital because of relapsed follicular lymphoma. Obinutuzumab (OBZ) and bendamustine (GB) therapy was administered for her lymphoma, and thrombocytopenia requiring platelet transfusion was observed after the first course. Although the dose of bendamustine had been reduced, her thrombocytopenia was observed again after the second course. Complete remission of her lymphoma was achieved after 4 courses of GB therapy, and the patient was switched to OBZ maintenance therapy. Nevertheless, thrombocytopenia was observed again during the maintenance therapy with OBZ alone. Observing the platelet count that changed over time after OBZ administration in detail, the platelet count started to decrease 1 hour after the end of OBZ administration, decreased to half after 6 hours, reached the lowest value 4 days after administration, and gradually recovered from 10 days after administration. Although OBZ administration-associated thrombocytopenia is a relatively common complication, acute thrombocytopenia up to 24 hours after administration is rare. However, as in this case, thrombocytopenia may progress in an extremely short time after administration, and it is necessary for clinicians to pay attention to OBZ treatment.